1. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer

   • Nancy Egerton

   Mini Review Open access 01 October 2010 Pages: 1005 - 1012

2. Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93)

   • Ritesh Rathore
   • Ariel Birnbaum
   • Neal Ready

   Original Article 04 February 2010 Pages: 1013 - 1017

3. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer

   • Elaine T. Lam
   • Jessie L.- S. Au
   • Miguel A. Villalona-Calero

   Original Article 28 January 2010 Pages: 1019 - 1029

   

4. Zonula Occludens-1 alterations and enhanced intestinal permeability in methotrexate-treated rats

   • Kazuma Hamada
   • Yoshihisa Shitara
   • Toshiharu Horie

   Original Article 30 January 2010 Pages: 1031 - 1038

   

5. Bendamustine pharmacokinetic profile and exposure–response relationships in patients with indolent non-Hodgkin’s lymphoma

   • Joel S. Owen
   • Murad Melhem
   • Bradley Kahl

   Original Article 06 February 2010 Pages: 1039 - 1049

   

6. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

   • Andrew H. Ko
   • Alan P. Venook
   • Margaret A. Tempero

   Original Article 04 February 2010 Pages: 1051 - 1057

   

7. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma

   • Olivier Mir
   • Stanislas Ropert
   • François Goldwasser

   Original Article 13 February 2010 Pages: 1059 - 1063

8. An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma

   • Seiji Naito
   • Taiji Tsukamoto
   • Hideyuki Akaza

   Original Article 16 February 2010 Pages: 1065 - 1070

   

9. Sonodynamically induced apoptosis and active oxygen generation by gallium–porphyrin complex, ATX-70

   • Nagahiko Yumita
   • Kazuho Okudaira
   • Shin-ichiro Umemura

   Original Article 05 March 2010 Pages: 1071 - 1078

   

10. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies

    • Paul K. Paik
    • Charles M. Rudin
    • Lee M. Krug

    Original Article 18 February 2010 Pages: 1079 - 1085

11. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement

    • Apostolia M. Tsimberidou
    • Stacy Moulder
    • Razelle Kurzrock

    Original Article 04 March 2010 Pages: 1087 - 1093

    

12. Inhibition of established subcutaneous murine tumour growth with topical Melaleuca alternifolia (tea tree) oil

    • Sara J. Greay
    • Demelza J. Ireland
    • Manfred W. Beilharz

    Original Article 21 February 2010 Pages: 1095 - 1102

    

13. Resistance to platinum-based chemotherapy in lung cancer cell lines

    • Jianli Chen
    • Nashwa Emara
    • Henry Simpkins

    Original Article 21 February 2010 Pages: 1103 - 1111

    

14. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol

    • Mark A. Dickson
    • Manish A. Shah
    • Gary K. Schwartz

    Original Article 21 February 2010 Pages: 1113 - 1121

15. Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma

    • Hidenari Nagai
    • Teppei Matsui
    • Yasukiyo Sumino

    Original Article 24 February 2010 Pages: 1123 - 1129

    

16. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer

    • Yi-kang Shi
    • Zhong-hua Li
    • Peng Wang

    Original Article 14 September 2010 Pages: 1131 - 1140

    

17. Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer

    • Laurent Claret
    • Jian-Feng Lu
    • René Bruno

    Original Article 25 September 2010 Pages: 1141 - 1149

    

18. Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients

    • Jian-Feng Lu
    • Laurent Claret
    • Yu-Nien Sun

    Original Article 25 September 2010 Pages: 1151 - 1158

    

19. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study

    • Yoshihiro Tanaka
    • Kazuhiro Yoshida
    • Takao Takahashi

    Clinical Trial Report Open access 28 September 2010 Pages: 1159 - 1165

20. Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study

    • Arantza Fariña-Sarasqueta
    • Gesina van Lijnschoten
    • Adriaan J. C. van den Brule

    Short Communication 28 July 2010 Pages: 1167 - 1171

    

21. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?

    • Rao N. V. S. Mamidi
    • Steve Weng
    • Man-Cheong Fung

    Short Communication 27 July 2010 Pages: 1173 - 1184